Versor Investments’s Pacira BioSciences PCRX Stock Holding History

Versor Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,900	Closed	-$489K	–	429
2025 Q4	$489K	Buy	+18,900	New	+$449K	0.08%	338
2024 Q1	–	Sell	-12,692	Closed	-$428K	–	839
2023 Q4	$428K	Buy	12,692 +4,397	+53%	+$129K	0.09%	386
2023 Q3	$254K	Sell	8,295 -4,474	-35%	-$161K	0.05%	528
2023 Q2	$512K	Sell	12,769 -1,075	-8%	-$44.4K	0.09%	252
2023 Q1	$565K	Sell	13,844 -2,203	-14%	-$87.6K	0.07%	283
2022 Q4	$620K	Buy	+16,047	New	+$781K	0.05%	277
2022 Q3	–	Sell	-4,200	Closed	-$245K	–	909
2022 Q2	$245K	Buy	+4,200	New	+$275K	0.01%	692
2020 Q2	–	Sell	-14,732	Closed	-$494K	–	273
2020 Q1	$494K	Buy	+14,732	New	+$612K	0.03%	114

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Versor Investments's PCRX Position: Q1 2026 in Review

Versor Investments sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 18,900 shares — an estimated $489K sold.

Versor Investments first reported a position in PCRX in Q1 2020 and held it in 8 quarters. The position peaked at $620K in Q4 2022. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Versor Investments reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Versor Investments sold 18,900 Pacira BioSciences shares in Q1 2026, an estimated $489K.
Versor Investments first reported a position in Pacira BioSciences in Q1 2020 and held it in 8 quarters.
Versor Investments's Pacira BioSciences position peaked at $620K in Q4 2022.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Versor Investments's 13F filing for Q1 2026, filed 12 May 2026.